The vitamin K2 market is estimated to be USD 139.6 million in 2024 and poised to achieve a 13.7% CAGR, reaching USD 264.7 million by 2029. As people become more informed about the role of vitamins in preventing chronic diseases, there is a heightened demand for Vitamin K2 due to its critical function in bone and cardiovascular health. Awareness campaigns and educational programs significantly contribute to this trend, emphasizing the benefits of vitamin K2 in maintaining calcium balance and reducing the risk of osteoporosis and arterial calcification.
The global demographic shift towards an aging population is another significant factor propelling the vitamin K2 market. Older adults are more susceptible to bone density loss and cardiovascular diseases, conditions that Vitamin K2 helps mitigate. As life expectancy increases, so does the need for nutritional supplements that support healthy aging. Consequently, the market for vitamin K2 is experiencing substantial growth as it becomes an integral component of the dietary regimen for the elderly.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=80962397
Based on product type, the MK 7 segment is projected to be the dominating segment in the market.
Vitamin K2 MK-7, specifically MenaQ7 and vitaMK7, represents a pivotal advancement in nutritional science, renowned for its dual benefits in bone and cardiovascular health. Distinct from its K1 counterpart, K2 MK-7's superior bioavailability and extended half-life in the body make it optimal for promoting calcium utilization towards bone strength while preventing arterial calcification. Its role in activating key proteins like osteocalcin and Matrix Gla Protein (MGP) underscores its efficacy in supporting skeletal integrity and cardiovascular flexibility.
As consumer awareness grows and dietary deficiencies persist, the market potential for K2 MK-7 continues to expand, driven by increasing demand for scientifically validated supplements that address fundamental health challenges across diverse demographic segments.
The pharmaceutical segment in the vitamin K2 market is projected to have significant growth in the forecasted period.
Vitamin K2 has shown various potential benefits in pharmaceutical applications, which are estimated to drive the demand for this ingredient in this industry. However, there is a stringent regulatory structure for the usage of vitamin K2 in pharmaceutical applications across the regions. Multiple primary industry experts from various vitamin K2 manufacturers agreed that the usage of vitamin K2 in pharmaceutical applications is limited to Asia Pacific; within this region, although some countries manufacture vitamin K2 for pharmaceutical applications, the consumption is mainly observed in China and Japan. Thus, considering recent government insights, along with ongoing research and clinical trials, supports the potential benefits of vitamin K2 in pharmaceutical applications.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=80962397
Asia Pacific is the fastest-growing market for vitamin K2 among the regions.
The Asia Pacific region is emerging as the fastest-growing market for vitamin K2, driven by a combination of demographic, economic, and lifestyle factors. One of the primary drivers of this growth is the regionâs rapidly aging population. Countries such as Japan, China, and South Korea are experiencing significant increases in their elderly populations, who are more prone to bone-related ailments like osteoporosis and cardiovascular issues. This demographic shift is creating a substantial demand for nutritional supplements that support bone health and prevent arterial calcification, making vitamin K2 a sought-after nutrient.
Additionally, the robust growth of the e-commerce sector in the Asia Pacific (APAC) region has significantly facilitated easy access to a wide range of vitamin K2 products, contributing to the market's expansion. One of the main advantages is the proliferation of online retail platforms, such as Amazon, Alibaba, and other regional e-commerce giants. These platforms have not only increased the visibility of vitamin K2 supplements but have also allowed for a broader distribution network, reaching consumers in even the most remote areas.
The key players in the market are Gnosis by Lesaffre (NattoPharma) (France), Kappa Bioscience AS (Balchem Corp.) (US), J-Oil Mills, INC. (PLT Health Solutions, Inc.) (Japan), Novozymes A/S, part of Novonesis Group (Denmark), Sungen Bioscience Co., Ltd. (China), Vesta Nutra (US), Richen Nutritional Technology Co., Ltd. (China), Menadiona (Spain), GF Fermentech (GenoFocus) (Korea), AngelYeast Co., Ltd. (China), GeneFerm Biotechnology Co., Ltd. (Taiwan), Nakoda Chemical Ltd. (India), Haihang Industry Co., Ltd. (China), Chemicea Limited (India), and Kyowa Hakko U.S.A., Inc. (US).
